Category: Federal Forum Posters
Purpose: The focus of care for patients diagnosed with metastatic cancer should be largely centered on quality of life and simplifying medication regimens to provide comfort and support. The objective of this study is to evaluate the incidence of palliative antineoplastic therapy administration for metastatic lung cancer, prostate cancer, colon cancer, pancreatic cancer, and melanoma, and the number of patients who received non-essential medications at thirty and fourteen days prior to death.
Methods: This is a retrospective, multicenter study that will be submitted to the Research & Development Committee and Institutional Review Board (IRB) at individual Veteran Affairs Medical Center for approval. The electronic medical record system will identify patients deceased between July 1, 2016 to June 30, 2018 with metastatic lung, colorectal, prostate, pancreatic cancer, or melanoma. Further review of eligible patients will be screened and evaluated to determine the proportion of Veterans who received palliative antineoplastic therapy and non-essential chronic medications within the last 30 and 14 days of life. Data will be collected includes: patient’s age at death, gender, cancer diagnosis, hospice care referral, emergency visits related to cancer or cancer treatment, and antineoplastic therapy and non-essential medications administered within 30 and 14 days of death. Antineoplastic therapy are defined as intravenous chemotherapy, oral targeted-therapy, or immunotherapy. Non-essential medications will include lipid-lowering agents, oral bisphosphonates, vitamin supplements, anti-platelet agents, anti-dementia agents, gastric protectors without symptom-related indication, oral anti-diabetic agents with most recent A1C < 8%, and therapeutic medication duplications.
Thao Truong– PGY1 Pharmacy Resident, Southern Arizona VA Health Care System, Tucson, AZ